TIGIT and neoplasm: The results from preclinical tumor models presented that therapeutic targeting of CD96 and TIGIT has demonstrated significant efficacy and synergistic activity with PD-1 inhibition, which could restore T cell exhaustion to a certain extent [75, 76].